Inactive Instrument

Highlights Apexigen, Inc.

Equities

APGN

US03759B1026

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Pyxis Oncology Completes Acquisition of Apexigen	23-08-23	MT
Pyxis Oncology, Inc. completed the acquisition of Apexigen, Inc. from entities associated with Pfizer Inc., Lincoln Park Capital, LLC, managed by Laurion Capital Management LP, Bayer World Investments B.V. and others.	23-08-22	CI
Apexigen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Apexigen, Inc. Announces Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma Presented at the American Society of Clinical Oncology 2023 Annual Meeting	23-06-03	CI
Pyxis Oncology to Acquire Apexigen in $16 Million All-Stock Deal	23-05-24	MT
Apexigen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Apexigen Announces Review of Strategic Alternatives	23-02-27	CI
Apexigen Plans to Reduce its Workforce by 55%	23-02-27	CI
Apexigen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-22	CI
Apexigen Announces New Phase 2 Data Evaluating Sotigalimab, Its CD40 Agonist Antibody, At ASCO Gastrointestinal Cancers Symposium 2023	23-01-19	CI
Apexigen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Apexigen, Inc. Announces Positive Interim Results from Phase 2 Trial Evaluating Its Cd40 Antibody, Sotigalimab, in Combination with Doxorubicin in Patients with Liposarcoma	22-11-14	CI
Apexigen, Inc. Announces New Data from a Phase 1/2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Pembrolizumab in Patients with First-Line Metastatic Melanoma at the SITC 2022 Annual Meeting	22-11-11	CI
Apexigen, Inc. Announces New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Neoadjuvant Chemoradiation in Patients with Resectable Esophageal and Gastroesophageal Junction Cancers at ESMO Congress 2022	22-09-05	CI
Apexigen Inc. completed the acquisition of Brookline Capital Acquisition Corp. from Brookline Capital Holdings, LLC, Periscope Capital Inc, Kepos Capital LP and others in a reverse merger transaction.	22-07-28	CI
Apexigen Inc. entered into a non-binding letter of intent to acquire Brookline Capital Acquisition Corp. from Brookline Capital Holdings, LLC, Periscope Capital Inc, Kepos Capital LP and others for approximately $210 million in a reverse merger transaction.	22-03-17	CI
Neon Therapeutics and Apexigen Announce First Patient Dosed in Neon’s NT-003 Phase 1b Combination Trial of NEO-PV-01 in Metastatic Melanoma	18-12-06	CI
Neon Therapeutics, Inc. and Apexigen, Inc. Announce Immuno-Oncology Clinical Trial Collaboration	17-07-25	CI
Bristol-Myers Squibb and Apexigen, Inc. Announce Clinical Collaboration to Evaluate Opdivo in Combination with APX005M in Advanced Solid Tumors	17-04-11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Like the pros, access all the transcripts and spot the best opportunities before anyone else.

Unlock them now!

fermer